

RITE AID CORPORATION AND SUBSIDIARIES  
SUPPLEMENTAL INFORMATION  
RECONCILIATION OF NET LOSS GUIDANCE TO ADJUSTED EBITDA GUIDANCE  
YEAR ENDING FEBRUARY 27, 2021  
(In thousands)  
(unaudited)

	Guidance Range	
	Low	High
Total Revenues	\$ 23,975,000	\$ 24,000,000
PBM Revenues	\$ 7,850,000	\$ 7,950,000
Same store sales	3.40%	3.50%
Gross Capital Expenditures	\$ 315,000	\$ 315,000
Reconciliation of net loss to adjusted EBITDA:		
Net loss	\$ (100,000)	\$ (90,000)
Adjustments:		
Interest expense	201,000	201,000
Income tax benefit	(10,000)	(10,000)
Depreciation and amortization	327,000	327,000
LIFO credit	(52,000)	(52,000)
Lease termination and impairment charges	57,000	57,000
Intangible asset impairment charges	30,000	30,000
Gain on debt modifications and retirements, net	(5,000)	(5,000)
Merger and Acquisition-related costs	10,000	10,000
Restructuring-related costs	85,000	85,000
Gain on sale of assets, net	(70,000)	(70,000)
Gain on Bartell Drug acquisition	(61,000)	(61,000)
Other	13,000	13,000
Adjusted EBITDA	<u>\$ 425,000</u>	<u>\$ 435,000</u>

The above adjustments may differ from the final amounts to be released in conjunction with our earnings release on April 15, 2021, and such differences could be material.